Enorama Pharma AB (OSTO:ERMA) E10: kr-2.76 (As of Mar. 2026)


OSTO:ERMA Enorama Pharma AB OSTO:ERMA
28 GF Score
Price kr0.29
GF Value kr0.42
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Enorama Pharma AB E10?

Enorama Pharma AB OSTO:ERMA +13.33% 28 E10 is kr-2.76 as of Mar. 2026. GuruFocus rates OSTO:ERMA with a GF Score™ of 28/100 and a GF Value™ of kr0.42 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Enorama Pharma AB's adjusted earnings per share data for the three months ended in Mar. 2026 was kr-0.170. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr-2.76 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-30), Enorama Pharma AB's current stock price is kr0.289. Enorama Pharma AB's E10 for the quarter that ended in Mar. 2026 was kr-2.76. Enorama Pharma AB's Shiller PE Ratio of today is .


Enorama Pharma AB  (OSTO:ERMA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Enorama Pharma AB E10 Related Terms


Enorama Pharma AB E10 Historical Data

* Premium members only.

The historical data trend for Enorama Pharma AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enorama Pharma AB E10 Chart

Enorama Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.72 -2.82

Enorama Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.74 -2.77 -2.77 -2.82 -2.76

OSTO:ERMA vs ZTS, UTHR, VTRS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enorama Pharma AB Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Enorama Pharma AB's Shiller PE Ratio falls into.


OSTO:ERMA
28GF Score
Enorama Pharma AB OSTO:ERMA
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enorama Pharma AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enorama Pharma AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.17/133.3862*133.3862
=-0.170

Current CPI (Mar. 2026) = 133.3862.

Enorama Pharma AB Quarterly Data

per share eps CPI Adj_EPS
201606 -0.609 101.019 -0.804
201609 -0.198 101.138 -0.261
201612 -0.333 102.022 -0.435
201703 -0.276 102.022 -0.361
201706 -0.324 102.752 -0.421
201709 -0.379 103.279 -0.489
201712 -0.516 103.793 -0.663
201803 -0.509 103.962 -0.653
201806 -0.525 104.875 -0.668
201809 -0.566 105.679 -0.714
201812 -1.035 105.912 -1.303
201903 -0.695 105.886 -0.876
201906 -0.630 106.742 -0.787
201909 -1.123 107.214 -1.397
201912 -1.075 107.766 -1.331
202003 -0.800 106.563 -1.001
202006 -0.630 107.498 -0.782
202009 -0.711 107.635 -0.881
202012 -1.203 108.296 -1.482
202103 -0.816 108.360 -1.004
202106 -0.711 108.928 -0.871
202109 -1.075 110.338 -1.300
202112 -0.847 112.486 -1.004
202203 -1.147 114.825 -1.332
202206 -1.123 118.384 -1.265
202209 -0.776 122.296 -0.846
202212 -1.132 126.365 -1.195
202303 -0.390 127.042 -0.409
202306 -0.300 129.407 -0.309
202309 -0.330 130.224 -0.338
202312 -0.340 131.912 -0.344
202403 -0.170 132.205 -0.172
202406 -0.110 132.716 -0.111
202409 -0.120 132.304 -0.121
202412 -0.360 132.987 -0.361
202503 -0.370 132.825 -0.372
202506 -0.280 133.699 -0.279
202509 -0.180 133.482 -0.180
202512 -0.280 133.386 -0.280
202603 -0.170 133.386 -0.170

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of kr-2.76 mean?
Enorama Pharma AB (OSTO:ERMA) has a E10 of kr-2.76 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Enorama Pharma AB and its competitors.
Is Enorama Pharma AB's E10 too high?
Enorama Pharma AB's current E10 is kr-2.76. Overall, Enorama Pharma AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's E10 compare to ZTS and UTHR?
Enorama Pharma AB's E10 of kr-2.76 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Enorama Pharma AB and its competitors. Enorama Pharma AB's current E10 is kr-2.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.42, compared to a current price of kr0.29 — trading 31.2% below its estimated fair value. The current E10 is kr-2.76. Enorama Pharma AB's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current E10 is kr-2.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?

Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued. The current stock price of kr0.29 is trading 31.2% below its estimated GF Value™ of kr0.42. GuruFocus considers Enorama Pharma AB to be Possible Value Trap.

Key valuation signals for OSTO:ERMA:

  • E10: kr-2.76
  • GF Value™: kr0.42 vs. price of kr0.29 (31.2% below fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enorama Pharma AB Business Description

Address Vastra Varvsgatan 19, Malmo, SWE, SE-211 77
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
28GF Score

Get the complete analysis for OSTO:ERMA

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.29
Price
kr0.42
GF Value